Pramodini Medicare IPO: Price Band, Lot Size, Financials & Review
Pramodini Medicare IPO listed on NSE on Wed, 19 Aug 2026. The issue was subscribed 3.96x overall.
- Open Date
- 12 Aug 2026
- Close Date
- 14 Aug 2026
Last updated
- Price band
- ₹110 – ₹118
- Lot size
- 1,200 shares
- Min. investment
- ₹2,83,200
- Issue size
- ₹69.04 Cr
- Last GMP
- 0
- Subscribed
- 🔥 3.96x
Pramodini Medicare IPO details
Pramodini Medicare IPO is a ₹69.04 Cr book-building IPO on the SME segment, listing on NSE. It combines a fresh issue of ₹63.14 Cr (91.45%) with an offer for sale of ₹5.9 Cr (8.55%) by existing shareholders. Only the fresh issue money goes to the company.
The issue was open from Wed, 12 Aug 2026 to Fri, 14 Aug 2026. Allotment was finalised on Mon, 17 Aug 2026, and the shares listed on NSE on Wed, 19 Aug 2026.
The price band is ₹110 to ₹118 per share and the lot size is 1200 shares, so the minimum retail application is ₹2,83,200. Retail investors can apply for up to 2 lots (2,400 shares, ₹2,83,200).
Purva Sharegistry India Pvt Ltd is the registrar, and Smart Horizon Capital Advisors Private Limited is the book running lead manager.
Grey market premium (GMP)
Day-wise GMP →The last Pramodini Medicare IPO GMP before listing was 0 (0.00% against the upper price band of ₹118), implying an estimated listing price of ₹118. Across 10 days of tracking, GMP ranged from 0 (04 Aug) to 0 (04 Aug).
| Last GMP | 0 |
|---|---|
| GMP vs upper band | 0.00% |
| Estimated listing price | ₹118 |
| Highest (04 Aug) | 0 |
| Lowest (04 Aug) | 0 |
Grey market trading is unofficial and unregulated. GMP is a sentiment indicator, not a guarantee of the listing price. See the Pramodini Medicare IPO day-wise GMP.
Subscription
Day-wise subscription →Pramodini Medicare IPO was subscribed 3.96x overall: QIB 3.66x, NII 5.31x and retail 3.49x.
| Category | Subscribed |
|---|---|
| QIB | 3.66x |
| NII | 5.31x |
| └ bNII (above ₹10 lakh) | 5.55x |
| └ sNII (₹2–10 lakh) | 4.82x |
| Retail | 3.49x |
| Total | 3.96x |
Final figures at the close of bidding on 14 Aug 2026. Category-wise bids, application-wise breakup and allotment chances are on the Pramodini Medicare IPO day-wise and category-wise subscription page.
Share reservation by category
| Category | Shares offered | Share of issue |
|---|---|---|
| Anchor Investors | 13,60,800 | 24.67% |
| Qualified Institutions | 11,71,200 | 21.24% |
| Non-Institutional | 9,60,000 | 17.41% |
| └ BNII | 6,39,600 | 11.60% |
| └ SNII | 3,20,400 | 5.81% |
| Retail Investors | 20,23,200 | 36.68% |
| Total | 55,15,200 | 100.00% |
Shares offered include the anchor investor portion, which is allotted a day before the issue opens. Subscription figures exclude anchors, so category sizes on the subscription page are smaller.
Pramodini Medicare IPO lot size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 2,400 | ₹2,83,200 |
| Retail (Max) | 2 | 2,400 | ₹2,83,200 |
| S-HNI (Min) | 3 | 3,600 | ₹4,24,800 |
| S-HNI (Max) | 7 | 8,400 | ₹9,91,200 |
| B-HNI (Min) | 8 | 9,600 | ₹11,32,800 |
Amounts at the upper end of the price band.
Issue structure and valuation
It combines a fresh issue of ₹63.14 Cr (91.45%) with an offer for sale of ₹5.9 Cr (8.55%) by existing shareholders. Only the fresh issue money goes to the company.
At the upper price band of ₹118, the issue is priced at 11.34x pre-issue earnings and 14.97x post-issue earnings per share.
The post-issue P/E is higher because the fresh issue adds new shares, which spreads the same profit over more shares.
Listed peers with positive earnings trade at a median P/E of 13.62x (3 companies).
Promoter holding falls from 85.71% before the issue to 62.64% after it.
| EPS (pre-issue) Latest earnings per share before the issue | ₹10.41 |
|---|---|
| P/E (pre-issue) Upper price band ÷ pre-issue EPS | 11.34x |
| EPS (post-issue) EPS on the enlarged share capital | ₹7.88 |
| P/E (post-issue) Upper price band ÷ post-issue EPS | 14.97x |
| Promoter holding (pre-issue) | 85.71% |
| Promoter holding (post-issue) | 62.64% |
Pramodini Medicare Limited financials
Between 31 Mar 2025 and 31 Mar 2026, Income rose from ₹38.55 Cr to ₹63.38 Cr, and profit after tax rose from ₹11.14 Cr to ₹17.38 Cr. The PAT margin for 31 Mar 2026 was 27.42%.
| Period ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 93.62 | 56.45 | 48.78 |
| Total Income | 63.38 | 38.55 | 35.79 |
| Profit After Tax | 17.38 | 11.14 | 7.14 |
| EBITDA | 30.90 | 20.97 | 15.53 |
| Net Worth | 53.15 | 35.77 | 24.75 |
| Reserve & Surplus | 36.46 | 34.49 | 23.46 |
| Total Borrowings | 17.85 | 10.81 | 11.96 |
₹ in crore, as stated in the prospectus.
Key performance indicators
| KPI | Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|---|
| ROE % | 39.08 | 36.44 | 32.76 |
| ROCE % | 34.66 | 36.48 | 31.90 |
| Debt / Equity | 0.34 | 0.30 | 0.30 |
| RoNW % | 32.69 | 30.83 | 28.00 |
| Pat Margin % | 27.90 | 28.84 | 19.67 |
Peer comparison
| Company | Face value | P/E | EPS (basic) | EPS (diluted) | RoNW | NAV |
|---|---|---|---|---|---|---|
| Pramodini Medicare Ltd | 10 | — | 10.41 | 10.41 | 32.69% | 31.84 |
| Invicta Diagnostic Ltd | 10 | 13.62 | 4.90 | 4.90 | 9.76% | 39.71 |
| Krsnaa Diagnostics Ltd | 5 | 16.74 | 31.30 | 31.30 | 10.35% | 302.23 |
| Star Imaging & Path Labs Ltd | 10 | 7.87 | 11.05 | 11.05 | 16.58% | 66.65 |
From the prospectus. P/E is shown as — when earnings are zero or negative, or not reported for the issuer before listing.
Objectives
The company intends to allocate the net proceeds from the offering to the following objectives.
| Sr | Objective |
|---|---|
| 1 |
About Pramodini Medicare Limited
Incorporated in 2000, Pramodini Medicare Limited is an Indian diagnostic healthcare service provider offering technology-enabled diagnostic solutions across the radiology, clinical laboratory, and nuclear medicine segments. The company caters to a diverse customer base, including government hospitals, private hospitals, public sector undertakings (PSUs), medical colleges, and private diagnostic centres across Tier I, Tier II, and Tier III cities in India.
Service Portfolio
The company's comprehensive range of diagnostic services includes:
- Radiology Services: MRI, CT Scan, X-ray, Ultrasound with Colour Doppler, Mammography, DEXA Scan, and Interventional Radiology.
- Clinical Laboratory Services: Haematology, Microbiology, Immunology, Pathology, and Biochemistry.
- Nuclear Medicine Services: PET-CT, SPECT, and Nuclear Therapy.
Pramodini Medicare Limited also operates a 24×7 Teleradiology Centre and a Central Processing Laboratory in Vijayawada, enabling timely reporting and efficient diagnostic support across its network.
Business Model
The company operates through four key business models:
- Public-Private Partnership (PPP): Operates diagnostic centres within government hospitals and medical colleges under long-term Memorandums of Understanding (MOUs).
- Private-Private Partnership (Pvt-Pvt): Establishes and manages diagnostic centres within private hospitals through partnership agreements.
- Strategic Partnerships with Public Sector Undertakings (PSUs): Collaborates with Government of India PSUs to establish and operate diagnostic and imaging centres across multiple states.
- Standalone Diagnostic Centres: Owns and operates independent diagnostic centres and laboratories that provide services directly to patients as well as hospitals.
Each diagnostic centre functions under a separate agreement or MOU, with contractual terms tailored to the specific location and operating requirements.
Operations
As of August 4, 2026, Pramodini Medicare Limited operated 16 diagnostic centres across seven Indian states, providing a broad spectrum of diagnostic services through its integrated healthcare network.
Workforce
As of March 31, 2026, the company employed 161 permanent employees.
Promoters
- Chalasani Durga Aashritha
- Chalasani Kavitha
- Chalasani Kuldeep Kumar
- Chalasani Lalithakumar
- Sri Ram Medicare Pvt.Ltd.
Contact details
Pramodini Medicare Ltd
D. No: - 29-4-54K, CSI Complex,
Prakasam Road,
Suryaraopet
Vijayawada, Andhra Pradesh, 520002
Telephone: +91 9985782727
Email: investors@pramodinidiagnostics.com
Website: http://www.pramodinidiagnostics.com/
Pramodini Medicare IPO FAQs
- What is the Pramodini Medicare IPO price band?
- The Pramodini Medicare IPO price band is ₹110 to ₹118 per share.
- What is the Pramodini Medicare IPO lot size and minimum investment?
- The Pramodini Medicare IPO lot size is 1200 shares. The minimum retail investment is ₹2,83,200 for one lot at the upper price band. Retail investors can apply for up to 2 lots (2,400 shares), costing ₹2,83,200.
- When was Pramodini Medicare IPO open for subscription?
- Pramodini Medicare IPO was open for subscription from Wed, 12 Aug 2026 to Fri, 14 Aug 2026.
- What is the Pramodini Medicare IPO subscription status?
- Pramodini Medicare IPO was subscribed 3.96x overall: QIB 3.66x, NII 5.31x and retail 3.49x. Day-wise and category-wise figures are on the subscription page.
- What was the Pramodini Medicare IPO GMP before listing?
- The last Pramodini Medicare IPO GMP before listing was 0 (0.00% against the upper price band of ₹118), implying an estimated listing price of ₹118. Across 10 days of tracking, GMP ranged from 0 (04 Aug) to 0 (04 Aug). GMP is an unofficial grey market indicator and can change quickly.
- What is the Pramodini Medicare IPO allotment date?
- The Pramodini Medicare IPO basis of allotment was finalised on Mon, 17 Aug 2026. You can check your allotment status on the Purva Sharegistry India Pvt Ltd website.
- What is the Pramodini Medicare IPO listing date?
- Pramodini Medicare IPO listed on NSE on Wed, 19 Aug 2026.
- Is the Pramodini Medicare IPO a fresh issue or an offer for sale?
- It combines a fresh issue of ₹63.14 Cr (91.45%) with an offer for sale of ₹5.9 Cr (8.55%) by existing shareholders. Only the fresh issue money goes to the company.
- Who are the registrar and lead managers of the Pramodini Medicare IPO?
- The registrar for the Pramodini Medicare IPO is Purva Sharegistry India Pvt Ltd, and the book running lead manager is Smart Horizon Capital Advisors Private Limited.
Data is compiled from the prospectus, stock exchanges and market sources and is for information only. It is not investment advice; read the RHP before applying.